NASDAQ:SGTX - Sigilon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $53.75
  • Forecasted Upside: 235.94 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$16.00
▼ -0.07 (-0.44%)
1 month | 3 months | 12 months
Get New Sigilon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$53.75
▲ +235.94% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sigilon Therapeutics in the last 3 months. The average price target is $53.75, with a high forecast of $62.00 and a low forecast of $45.00. The average price target represents a 235.94% upside from the last price of $16.00.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Sigilon Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021Canaccord GenuityInitiated CoverageBuy$62.00Low
i
12/29/2020BarclaysInitiated CoverageOverweight$48.00N/A
i
12/29/2020Morgan StanleyInitiated CoverageEqual Weight$45.00N/A
i
12/29/2020Jefferies Financial GroupInitiated CoverageBuy$60.00N/A
i
(Data available from 4/21/2016 forward)
Sigilon Therapeutics logo
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $16.00
$14.85
$16.41

50 Day Range

MA: $21.91
$16.07
$30.15

52 Week Range

Now: $16.00
$14.85
$54.32

Volume

58,592 shs

Average Volume

123,926 shs

Market Capitalization

$503.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sigilon Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Sigilon Therapeutics in the last year: Barclays PLC, Canaccord Genuity, Jefferies Financial Group Inc., Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for SGTX.

What is the current price target for Sigilon Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Sigilon Therapeutics in the last year. Their average twelve-month price target is $53.75, suggesting a possible upside of 235.9%. Canaccord Genuity has the highest price target set, predicting SGTX will reach $62.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $45.00 for Sigilon Therapeutics in the next year.
View the latest price targets for SGTX.

What is the current consensus analyst rating for Sigilon Therapeutics?

Sigilon Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGTX will outperform the market and that investors should add to their positions of Sigilon Therapeutics.
View the latest ratings for SGTX.

What other companies compete with Sigilon Therapeutics?

How do I contact Sigilon Therapeutics' investor relations team?

The company's listed phone number is 617-336-7540. The official website for Sigilon Therapeutics is sigilon.com.